.jpg)
.png)
All
I am honored as the Southwest Lipid Association President, in collaboration with the President of the Pacific Lipid Association, to bring you the first LipidSpin edition of 2024. I enthusiastically share these articles with the membership of the NLA, knowing the significant impact we as Lipid... more
Recently, the Dietary Guidelines Advisory Committee has re-evaluated its longstanding guidance about the avoidance of high-cholesterol foods, and has compiled a draft report that states cholesterol is no longer a nutrient of concern. This updated guidance is expected to be submitted to the... more
How many of you have taken the time to read, from front to back, the recent National Lipid Association (NLA) Recommendations for Patient-Centered Management of Dyslipidemia, Parts 1 and 2? Don’t be embarrassed, because I can’t see how few of you raised your hands. I had the good fortune to co-... more
Welcome to this edition of LipidSpin the MWLA has put together in partnership with our colleagues of the PLA focusing on atherogenic particles. LipidSpin is a fantastic opportunity to showcase collaborative work in the field of lipidology and this edition shows that lipidology is imperative to so... more
From TheHeart.org: Amsterdam, the Netherlands - An analysis of four phase-2 studies testing the effectiveness of AMG145 (Amgen), a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), showed the drug reduces LDL cholesterol by 43% to 64%, depending on the... more
Sanofi and Regeneron announced on Monday, Feb. 11 alirocumab will be made available at a reduced list price to help lower patient out-of-pocket costs and improve access.
.article-image{ display:inline-block; float:left; max-width:650px; padding-right:5px; margin-bottom:20px; } Caring for people is of the utmost importance to Dr. Wayne True, which is evident from his hectic daily schedule, volunteer mission work, and recent foray into the world of politics... more
Discuss the article at www.lipid.org/lipidspin Both genetic and observational studies have shown that elevated triglycerides (TG) are a marker of increased cardiovascular (CV) risk, even in statin-treated patients. (1) However, randomized clinical trials with TG-lowering drugs such as fibrates,... more